These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31679120)

  • 41. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.
    Benedek IH; Jobes J; Xiang Q; Fiske WD
    Drug Des Devel Ther; 2011; 5():455-63. PubMed ID: 22162639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
    Kinzler ER; Pantaleon C; Aigner S
    Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
    Mandema JW; Kaiko RF; Oshlack B; Reder RF; Stanski DR
    Br J Clin Pharmacol; 1996 Dec; 42(6):747-56. PubMed ID: 8971431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.
    Vosburg SK; Jones JD; Manubay JM; Ashworth JB; Shapiro DY; Comer SD
    Addiction; 2013 Jun; 108(6):1095-106. PubMed ID: 23316699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen.
    Couto JE; Webster L; Romney MC; Leider HL; Linden A
    J Opioid Manag; 2009; 5(6):359-64. PubMed ID: 20073409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain.
    Pergolizzi JV; Taylor R; Raffa RB
    Adv Ther; 2015 Jun; 32(6):485-95. PubMed ID: 26026272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
    Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
    Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding sequestered naltrexone.
    Gimbel JS; Rauck RL; Bass A; Wilson J; Pixton G; Malhotra B; Wilson G; Wolfram G
    J Opioid Manag; 2019; 15(5):417-427. PubMed ID: 31849032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies.
    Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T
    Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
    Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
    Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oxycodone DETERx
    Lamb YN; Garnock-Jones KP; Keam SJ
    Drugs; 2016 Dec; 76(18):1759-1769. PubMed ID: 27832472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.